Taking TP53 for example, supportive evidences include: 1) patients with carcinomas demonstrated better responses to bevacizumab treatment if carrying TP53 mutations [24]; 2) patients with sarcomas showed better responses to pazopanib treatment [25]. This evidence concerns the gene TP53 and carcinoma.